retatrutide phase 2 type 2 diabetes weight loss 2024 ESC 2024: improves lipid and cardiovascular risk profile in II trial VisualAbstract: Retatrutide reduces body weight

Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner

Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence

We monitor this closely so we can catch it early

& Exton, J

The recent cardiovascular risk reduction indication for Wegovy may eventually affect coverage policies, but statutory changes would be needed for broader Medicare coverage

Patients with health insurance may be eligible for the manufacturer's coupon, which can bring the cost down to just $25 per month